Vivus, Inc. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vivus with three other
companies in this sector in the United States:
Spring Pharmaceutical Group Inc
sales of $64.94 million
Akcea Therapeutics Inc
Lexicon Pharmaceuticals Incorporated
of which 100%
was Pharmaceutical R&D).
During the year ended December of 2018, sales at
Vivus were $65.06 million.
decrease of 0.5%
versus 2017, when the company's sales were $65.37 million.